Guardian Capital (Canada)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Guardian Capital (Canada)’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,687	Closed	-$1.27M	–	182
2021 Q4	$1.27M	Sell	1,687 -149	-8%	-$112K	0.02%	128
2021 Q3	$1.37M	Buy	1,836 +168	+10%	+$126K	0.03%	130
2021 Q2	$1.07M	Sell	1,668 -415	-20%	-$253K	0.02%	136
2021 Q1	$1.19M	Buy	2,083 +74	+4%	+$43.8K	0.02%	132
2020 Q4	$1.17M	Buy	2,009 +12	+0.6%	+$6.83K	0.03%	124
2020 Q3	$1.03M	Buy	1,997 +336	+20%	+$170K	0.03%	119
2020 Q2	$750K	Sell	1,661 -685	-29%	-$302K	0.02%	122
2020 Q1	$822K	Buy	2,346 +232	+11%	+$85.3K	0.02%	106
2019 Q4	$782K	Buy	2,114 +194	+10%	+$68.4K	0.02%	116
2019 Q3	$639K	Buy	+1,920	New	+$626K	0.01%	125

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Guardian Capital (Canada)'s BIO Position: Q1 2022 in Review

Guardian Capital (Canada) sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 1,687 shares — an estimated $1.27M sold.

Guardian Capital (Canada) first reported a position in BIO in Q3 2019 and held it in 10 quarters. The position peaked at $1.37M in Q3 2021. 514 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

Guardian Capital (Canada) reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
Guardian Capital (Canada) sold 1,687 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $1.27M.
Guardian Capital (Canada) first reported a position in Bio-Rad Laboratories Class A in Q3 2019 and held it in 10 quarters.
Guardian Capital (Canada)'s Bio-Rad Laboratories Class A position peaked at $1.37M in Q3 2021.
514 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Guardian Capital (Canada)'s 13F filing for Q1 2022, filed 16 May 2022.